Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression

Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection

(2015) Alan Winston et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Posicionamiento de dolutegravir en el tratamiento de la infección por el VIH

(2015) Esteban Martínez et al.   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

(2015) Camelia Gubavu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Current state and limitations of daily oral therapy for treatment

(2015) Daniel A. Solomon et al.   Current Opinion in HIV and AIDS

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

(2015) Nicholas I Paton et al.   Lancet HIV

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy

(2013) P Pugliese et al.   HIV MEDICINE

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

(2013) François Raffi et al.   LANCET INFECTIOUS DISEASES

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

(2013) Thibault Mesplède et al.   Retrovirology

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

The Ethics of Switch/Simplify in Antiretroviral Trials: Non-Inferior or Just Inferior?

(2012) Andrew Carr et al.   PLOS MEDICINE

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

(2011) P. K. Quashie et al.   JOURNAL OF VIROLOGY

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection

(2010) O. Turriziani et al.   CLINICAL MICROBIOLOGY AND INFECTION